Toll Free: 1-888-928-9744

Diabetic Foot Ulcers - Pipeline Review, H1 2016

Published: May 25, 2016 | Pages: 162 | Publisher: Global Markets Direct | Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Diabetic Foot Ulcers - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Diabetic Foot Ulcers - Pipeline Review, H1 2016', provides an overview of the Diabetic Foot Ulcers pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Diabetic Foot Ulcers, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Diabetic Foot Ulcers and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Diabetic Foot Ulcers
- The report reviews pipeline therapeutics for Diabetic Foot Ulcers by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Diabetic Foot Ulcers therapeutics and enlists all their major and minor projects
- The report assesses Diabetic Foot Ulcers therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Diabetic Foot Ulcers

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Diabetic Foot Ulcers
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Diabetic Foot Ulcers pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
 Table of Contents
Table of Contents 2 List of Tables 8 List of Figures 10 Introduction 11 Global Markets Direct Report Coverage 11 Diabetic Foot Ulcers Overview 12 Therapeutics Development 13 Pipeline Products for Diabetic Foot Ulcers - Overview 13 Pipeline Products for Diabetic Foot Ulcers - Comparative Analysis 14 Diabetic Foot Ulcers - Therapeutics under Development by Companies 15 Diabetic Foot Ulcers - Therapeutics under Investigation by Universities/Institutes 17 Diabetic Foot Ulcers - Pipeline Products Glance 18 Late Stage Products 18 Clinical Stage Products 19 Early Stage Products 20 Unknown Stage Products 21 Diabetic Foot Ulcers - Products under Development by Companies 22 Diabetic Foot Ulcers - Products under Investigation by Universities/Institutes 25 Diabetic Foot Ulcers - Companies Involved in Therapeutics Development 26 Adocia 26 Bayer AG 27 CardioVascular BioTherapeutics, Inc. 28 Celgene Corporation 29 CytoTools AG 30 Dipexium Pharmaceuticals LLC 31 EyeGene, Inc. 32 FirstString Research, Inc. 33 GlaxoSmithKline Plc 34 Human Stem Cells Institute 35 Innovaxis 36 Izun Pharmaceuticals Corporation 37 Karyopharm Therapeutics, Inc. 38 Lytix Biopharma AS 39 MediWound Ltd. 40 NovaLead Pharma Pvt. Ltd. 41 Oneness Biotech Co., Ltd. 42 Osiris Therapeutics, Inc. 43 Pherecydes Pharma SA 44 Plurogen Therapeutics, Inc. 45 Sanofi 46 Stratatech Corporation 47 TechnoPhage SA 48 TGV-Laboratories 49 Theravasc, Inc. 50 Tissue Therapies Limited 51 USV Limited 52 Vida Therapeutics Inc. 53 ViroMed Co., Ltd. 54 Diabetic Foot Ulcers - Therapeutics Assessment 55 Assessment by Monotherapy Products 55 Assessment by Target 56 Assessment by Mechanism of Action 58 Assessment by Route of Administration 60 Assessment by Molecule Type 62 Drug Profiles 64 ALLO-ASC - Drug Profile 64 Product Description 64 Mechanism of Action 64 R&D Progress 64 AP-102 - Drug Profile 65 Product Description 65 Mechanism of Action 65 R&D Progress 65 APO-2 - Drug Profile 66 Product Description 66 Mechanism of Action 66 R&D Progress 66 becaplermin - Drug Profile 68 Product Description 68 Mechanism of Action 68 R&D Progress 68 Biochaperone PDGF-BB - Drug Profile 69 Product Description 69 Mechanism of Action 69 R&D Progress 69 Cell Therapy to Activate Cathelicidin for Diabetic Foot Ulcers and Crural Ulcer - Drug Profile 70 Product Description 70 Mechanism of Action 70 R&D Progress 70 Cell Therapy to Activate VEGF for Venous Leg Ulcers and Diabetic Foot Ulcers - Drug Profile 72 Product Description 72 Mechanism of Action 72 R&D Progress 72 CL-05 - Drug Profile 73 Product Description 73 Mechanism of Action 73 R&D Progress 73 CODA-001 - Drug Profile 75 Product Description 75 Mechanism of Action 75 R&D Progress 75 CVBT-141B - Drug Profile 77 Product Description 77 Mechanism of Action 77 R&D Progress 77 Cyndacel-M - Drug Profile 79 Product Description 79 Mechanism of Action 79 R&D Progress 79 daprodustat - Drug Profile 81 Product Description 81 Mechanism of Action 81 R&D Progress 81 Drug for Diabetic Foot Ulcer - Drug Profile 83 Product Description 83 Mechanism of Action 83 R&D Progress 83 EG-Decorin - Drug Profile 84 Product Description 84 Mechanism of Action 84 R&D Progress 84 epidermal growth factor biosimilar - Drug Profile 85 Product Description 85 Mechanism of Action 85 R&D Progress 85 EscharEx - Drug Profile 86 Product Description 86 Mechanism of Action 86 R&D Progress 86 esmolol hydrochloride - Drug Profile 87 Product Description 87 Mechanism of Action 87 R&D Progress 87 Gene Therapy to Activate HIF-1 Alpha for Wound and Ulcers - Drug Profile 89 Product Description 89 Mechanism of Action 89 R&D Progress 89 Granexin - Drug Profile 90 Product Description 90 Mechanism of Action 90 R&D Progress 90 Heberprot-P - Drug Profile 92 Product Description 92 Mechanism of Action 92 R&D Progress 92 IMSP-001 - Drug Profile 93 Product Description 93 Mechanism of Action 93 R&D Progress 93 IZN-6D4 - Drug Profile 94 Product Description 94 Mechanism of Action 94 R&D Progress 94 LTX-109 - Drug Profile 95 Product Description 95 Mechanism of Action 95 R&D Progress 95 MT-003 - Drug Profile 97 Product Description 97 Mechanism of Action 97 R&D Progress 97 Mul-1867 - Drug Profile 98 Product Description 98 Mechanism of Action 98 R&D Progress 98 Neovasculgen - Drug Profile 99 Product Description 99 Mechanism of Action 99 R&D Progress 99 Nu-2 - Drug Profile 100 Product Description 100 Mechanism of Action 100 R&D Progress 100 Nu-3 - Drug Profile 101 Product Description 101 Mechanism of Action 101 R&D Progress 101 ON-101 - Drug Profile 102 Product Description 102 Mechanism of Action 102 R&D Progress 102 OTI-1501 - Drug Profile 103 Product Description 103 Mechanism of Action 103 R&D Progress 103 PDA-002 - Drug Profile 104 Product Description 104 Mechanism of Action 104 R&D Progress 104 pexiganan acetate - Drug Profile 105 Product Description 105 Mechanism of Action 105 R&D Progress 105 PluroGel N - Drug Profile 107 Product Description 107 Mechanism of Action 107 R&D Progress 107 PP-2351 - Drug Profile 108 Product Description 108 Mechanism of Action 108 R&D Progress 108 Recombinant Protein for Wounds, Bone Regeneration and Diabetic Ulcers - Drug Profile 109 Product Description 109 Mechanism of Action 109 R&D Progress 109 selinexor - Drug Profile 110 Product Description 110 Mechanism of Action 110 R&D Progress 110 sodium nitrite SR - Drug Profile 116 Product Description 116 Mechanism of Action 116 R&D Progress 116 Synthetic Peptide to Inhibit TIE-2 for Diabetic Foot Ulcers and Wounds - Drug Profile 118 Product Description 118 Mechanism of Action 118 R&D Progress 118 TP-102 - Drug Profile 119 Product Description 119 Mechanism of Action 119 R&D Progress 119 V-10 - Drug Profile 120 Product Description 120 Mechanism of Action 120 R&D Progress 120 VF-001 - Drug Profile 121 Product Description 121 Mechanism of Action 121 R&D Progress 121 Vivefoot - Drug Profile 122 Product Description 122 Mechanism of Action 122 R&D Progress 122 VM-202 - Drug Profile 123 Product Description 123 Mechanism of Action 123 R&D Progress 123 VTI-1000 Series - Drug Profile 125 Product Description 125 Mechanism of Action 125 R&D Progress 125 Diabetic Foot Ulcers - Recent Pipeline Updates 126 Diabetic Foot Ulcers - Dormant Projects 150 Diabetic Foot Ulcers - Discontinued Products 153 Diabetic Foot Ulcers - Product Development Milestones 154 Featured News & Press Releases 154 Mar 28, 2016: Dipexium Pharmaceuticals Announces Issuance of Locilex Patent in Japan 154 Feb 04, 2016: Dipexium Pharmaceuticals Reaches 75% Enrollment Milestone in Pivotal Phase 3 Clinical Trials 154 Feb 02, 2016: MediWound EscharEx Meets Primary Endpoint in Second Phase 2 Clinical Trial for the Debridement of Chronic and Hard-to-Heal Wounds 154 Jan 05, 2016: Izun Pharmaceuticals to Present at Biotech Showcase 2016 156 Oct 13, 2015: Izun Pharmaceuticals Announces Positive Results from Phase 2 Randomized Trial in Diabetic Foot Ulcers 156 Oct 06, 2015: Osiris Announces Initiation of a Phase III Trial for a New Investigational Drug, OTI-15-01, for the Treatment of Chronic Diabetic Foot Wounds 157 Oct 01, 2015: Dipexium Pharmaceuticals Reaches 50% Enrollment in Second Pivotal Phase 3 Clinical Trial 158 Sep 21, 2015: Dipexium Pharmaceuticals Presents Locilex Microbiology Data at ICAAC/ICC 2015 Conference 158 Sep 01, 2015: US FDA Approves Initiation of ViroMed's VM202 for Phase III Clinical Study of Chronic Non-Healing Ischemic Diabetic Foot Ulcer 159 Aug 20, 2015: Dipexium Pharmaceuticals Surpasses Treatment Of 50% Of Subjects In Pivotal Phase 3 Clinical Trial 160 Appendix 161 Methodology 161 Coverage 161 Secondary Research 161 Primary Research 161 Expert Panel Validation 161 Contact Us 161 Disclaimer 162
List of Tables
Number of Products under Development for Diabetic Foot Ulcers, H1 2016 13 Number of Products under Development for Diabetic Foot Ulcers - Comparative Analysis, H1 2016 14 Number of Products under Development by Companies, H1 2016 15 Number of Products under Development by Companies, H1 2016 (Contd..1) 16 Number of Products under Investigation by Universities/Institutes, H1 2016 17 Comparative Analysis by Late Stage Development, H1 2016 18 Comparative Analysis by Clinical Stage Development, H1 2016 19 Comparative Analysis by Early Stage Development, H1 2016 20 Comparative Analysis by Unknown Stage Development, H1 2016 21 Products under Development by Companies, H1 2016 22 Products under Development by Companies, H1 2016 (Contd..1) 23 Products under Development by Companies, H1 2016 (Contd..2) 24 Products under Investigation by Universities/Institutes, H1 2016 25 Diabetic Foot Ulcers - Pipeline by Adocia, H1 2016 26 Diabetic Foot Ulcers - Pipeline by Bayer AG, H1 2016 27 Diabetic Foot Ulcers - Pipeline by CardioVascular BioTherapeutics, Inc., H1 2016 28 Diabetic Foot Ulcers - Pipeline by Celgene Corporation, H1 2016 29 Diabetic Foot Ulcers - Pipeline by CytoTools AG, H1 2016 30 Diabetic Foot Ulcers - Pipeline by Dipexium Pharmaceuticals LLC, H1 2016 31 Diabetic Foot Ulcers - Pipeline by EyeGene, Inc., H1 2016 32 Diabetic Foot Ulcers - Pipeline by FirstString Research, Inc., H1 2016 33 Diabetic Foot Ulcers - Pipeline by GlaxoSmithKline Plc, H1 2016 34 Diabetic Foot Ulcers - Pipeline by Human Stem Cells Institute, H1 2016 35 Diabetic Foot Ulcers - Pipeline by Innovaxis, H1 2016 36 Diabetic Foot Ulcers - Pipeline by Izun Pharmaceuticals Corporation, H1 2016 37 Diabetic Foot Ulcers - Pipeline by Karyopharm Therapeutics, Inc., H1 2016 38 Diabetic Foot Ulcers - Pipeline by Lytix Biopharma AS, H1 2016 39 Diabetic Foot Ulcers - Pipeline by MediWound Ltd., H1 2016 40 Diabetic Foot Ulcers - Pipeline by NovaLead Pharma Pvt. Ltd., H1 2016 41 Diabetic Foot Ulcers - Pipeline by Oneness Biotech Co., Ltd., H1 2016 42 Diabetic Foot Ulcers - Pipeline by Osiris Therapeutics, Inc., H1 2016 43 Diabetic Foot Ulcers - Pipeline by Pherecydes Pharma SA, H1 2016 44 Diabetic Foot Ulcers - Pipeline by Plurogen Therapeutics, Inc., H1 2016 45 Diabetic Foot Ulcers - Pipeline by Sanofi, H1 2016 46 Diabetic Foot Ulcers - Pipeline by Stratatech Corporation, H1 2016 47 Diabetic Foot Ulcers - Pipeline by TechnoPhage SA, H1 2016 48 Diabetic Foot Ulcers - Pipeline by TGV-Laboratories, H1 2016 49 Diabetic Foot Ulcers - Pipeline by Theravasc, Inc., H1 2016 50 Diabetic Foot Ulcers - Pipeline by Tissue Therapies Limited, H1 2016 51 Diabetic Foot Ulcers - Pipeline by USV Limited, H1 2016 52 Diabetic Foot Ulcers - Pipeline by Vida Therapeutics Inc., H1 2016 53 Diabetic Foot Ulcers - Pipeline by ViroMed Co., Ltd., H1 2016 54 Assessment by Monotherapy Products, H1 2016 55 Number of Products by Stage and Target, H1 2016 57 Number of Products by Stage and Mechanism of Action, H1 2016 59 Number of Products by Stage and Route of Administration, H1 2016 61 Number of Products by Stage and Molecule Type, H1 2016 63 Diabetic Foot Ulcers Therapeutics - Recent Pipeline Updates, H1 2016 126 Diabetic Foot Ulcers - Dormant Projects, H1 2016 150 Diabetic Foot Ulcers - Dormant Projects (Contd..1), H1 2016 151 Diabetic Foot Ulcers - Dormant Projects (Contd..2), H1 2016 152 Diabetic Foot Ulcers - Discontinued Products, H1 2016 153


List of Figures
Number of Products under Development for Diabetic Foot Ulcers, H1 2016 13 Number of Products under Development for Diabetic Foot Ulcers - Comparative Analysis, H1 2016 14 Number of Products under Development by Companies, H1 2016 15 Comparative Analysis by Late Stage Development, H1 2016 18 Comparative Analysis by Clinical Stage Development, H1 2016 19 Comparative Analysis by Early Stage Products, H1 2016 20 Assessment by Monotherapy Products, H1 2016 55 Number of Products by Top 10 Targets, H1 2016 56 Number of Products by Stage and Top 10 Targets, H1 2016 56 Number of Products by Top 10 Mechanism of Actions, H1 2016 58 Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 58 Number of Products by Top 10 Routes of Administration, H1 2016 60 Number of Products by Stage and Top 10 Routes of Administration, H1 2016 60 Number of Products by Top 10 Molecule Types, H1 2016 62 Number of Products by Stage and Top 10 Molecule Types, H1 2016 62

To request a free sample copy of this report, please complete the form below.

This website is secure and your personal details are safe. Privacy policy

Global aerosol propellants market is anticipated to reach USD 24.8 billion by 2020, as per a new research report by Radiant Insights, Inc. Increasing popularity of personal care and cosmetics products such as hair sprays, deodorants and shaving cream

Read More...

Global non halogenated flame retardants market size is anticipated to be valued at USD 2.54 billion by 2020, as per a new research report by Radiant Insights, Inc. Increasing safety materials demand owing to low heat & smoke emission properties in c

Read More...

Global electric water heaters market is expected to be valued at USD 29,322.4 million by 2022, as per a new research report by Radiant Insights, Inc. Escalating demand across extensive range of domestic applications is expected to drive demand. Evolv

Read More...

Global FPGA market is anticipated to be valued at USD 9,882.5 million by 2020, as per a new research report by Radiant Insights, Inc. Increasing demand for customized IC’s is expected to drive the demand. Customized IC’s helps manufacturers to mo

Read More...

Global aquafeed market size is anticipated to be valued at USD 165.04 billion by 2022, as per a new research report by Radiant Insights, Inc. Increase in fish consumption for direct and indirect consumer applications is anticipated to drive the marke

Read More...
Choose License Type
Single User - US $2000
Multi User - US $4000
Why Choose Us

24/5 Research support

Get your queries resolved from an industry expert. Request for a free product review before report purchase.

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.

verify